 NESS ZIONA, Israel--BUSINESS WIRE--BiomX Inc. NYSE American: PHGE BiomX or the Company, a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020. 2020 was a tremendous year of growth for BiomX, as we expanded our pipeline with programs in cystic fibrosis and atopic dermatitis, both desi 